Shattuck Labs, Inc. has announced progress in its SL-325 program, with an Investigational New Drug (IND) filing expected in the third quarter of 2025. The company reported a cash balance of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback